Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could stop painful swelling attacks in rare disease

NCT ID NCT04618211

Symptom relief Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral medication called deucrictibant for quickly relieving swelling and pain attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if symptoms like skin swelling, skin pain, and belly pain improved more with the drug than with placebo within 4 hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

74 people

The number who actually took part.

Started

Feb 2021

Finished

Mar 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Signed and dated informed consent form 2. Diagnosis of HAE type I or II 3. Documented history of HAE attacks: at least three in the last 4 months, or at least two in the last 2 months prior to screening 4. Reliable access and experience to use standard of care acute attack medications Key Exclusion Criteria: 1. Pregnancy or breast-feeding 2. Clinically significant abnormal electrocardiogram 3. Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study 4. Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrollment 5. Positive serology for HIV or active infection with hepatitis B virus or hepatitis C virus 6. Abnormal hepatic function 7. Abnormal renal function 8. History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse 9. History of documented severe hypersensitivity to any medicinal product 10. Participation in any other investigational drug study within defined period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C1 esterase inhibitor deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

C1 inhibitor deficiency hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2 Hereditary Angioedema Types I and II hereditary angioedema with C1Inh deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C1 esterase inhibitor deficiency C1 inhibitor deficiency Hereditary angioedema Hereditary angioedema - type 1 Hereditary angioedema - type 2 Hereditary angioedema attack Hereditary angioedema type I Hereditary angioedema type II Hereditary angioedema types I and II Hereditary angioedema with C1 esterase inhibitor deficiency

Contacts and locations

Locations

  • Study site

    Birmingham, Alabama, 35209, United States

  • Study site

    Paradise Valley, Arizona, 85253, United States

  • Study site

    San Diego, California, 92122, United States

  • Study site

    Santa Monica, California, 90404, United States

  • Study site

    Walnut Creek, California, 94598, United States

  • Study site

    Chevy Chase, Maryland, 20815, United States

  • Study site

    St Louis, Missouri, 63141, United States

  • Study site

    Hershey, Pennsylvania, 17033, United States

  • Study site

    Sofia, Bulgaria

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    Ottawa, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Québec, Quebec, Canada

  • Study site

    Brno, Czechia

  • Study site

    Hradec Králové, Czechia

  • Study site

    Grenoble, France

  • Study site

    Montpellier, France

  • Study site

    Paris, France

  • Study site

    Berlin, Germany

  • Study site

    Dresden, Germany

  • Study site

    Frankfurt, Germany

  • Study site

    Mainz, Germany

  • Study site

    Ulm, Germany

  • Study site

    Budapest, Hungary

  • Study site

    Ashkelon, Israel

  • Study site

    Haifa, Israel

  • Study site

    Tel Aviv, Israel

  • Study site

    Monserrato, Italy

  • Study site

    Naples, Italy

  • Study site

    Amsterdam, Netherlands

  • Study site

    Krakow, Poland

  • Study site

    Barcelona, Spain

  • Study site

    Madrid, Spain

  • Study site

    Brighton, United Kingdom

  • Study site

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.